Company overview
What does ANGIODYNAMICS INC do?
ANGIODYNAMICS INC (ANGO) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
What does ANGIODYNAMICS INC do?
ANGIODYNAMICS INC (ANGO) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
What industry is ANGIODYNAMICS INC in?
Healthcare · Surgical & Medical Instruments & Apparatus
What was ANGIODYNAMICS INC's latest reported revenue?
$78.4M for Q1 2026, from 10-Q filed Apr 2, 2026.
What changed in the latest comparable period?
Revenue increased +8.9% ($72.0M to $78.4M; Q1 2025 vs Q1 2026).
Business model (from the public record)
Belvedere describes the business using the issuer’s SEC classification and the company description extracted from public filings. Segment mix, customer identity, and recurring-versus-transactional revenue are shown only when those facts are identified in the filing extract—not inferred.
Healthcare · Surgical & Medical Instruments & Apparatus · United States
Financial profile
- Revenue
- $78.4M 10-Q · Q1 2026 · Filed Apr 2, 2026
- Revenue growth YoY
- +8.9% Belvedere calculation · 10-Q · Q1 2026 · Filed Apr 2, 2026
- Gross margin
- +52.9% Belvedere calculation · 10-Q · Q1 2026 · Filed Apr 2, 2026
- Operating margin
- -16.5% Belvedere calculation · 10-Q · Q1 2026 · Filed Apr 2, 2026
- Net income
- -$8.1M 10-Q · Q1 2026 · Filed Apr 2, 2026
- Operating cash flow
- — Not identified in latest matched XBRL period
- Capex
- — Not identified in latest matched XBRL period
- Belvedere FCF
- — Not identified in latest matched XBRL period
- FCF margin
- — Not identified in latest matched XBRL period
- Cash
- $53.9M 10-K · May 31, 2026 · Filed Jul 14, 2026
- Debt
- — Not identified in latest matched XBRL period
- Net debt
- -$53.9M Belvedere calculation · 10-K · May 31, 2026 · Filed Jul 14, 2026
- Shares
- 41,700,419 10-K · May 31, 2026 · Filed Jul 14, 2026
Balance sheet snapshot
Cash $53.9M. Identified debt —. Net debt -$53.9M. Missing debt tags are not treated as a zero-debt capital structure.
Financial information is derived from public filings and other identified sources. Belvedere calculations may differ from company-defined non-GAAP measures. See methodology and source notes. Valuation multiples are omitted because a licensed market-data provider is not configured.
Latest filings
| Form | Filed | Period | Accession | Source |
|---|---|---|---|---|
| 4 | Jul 31, 2026 | Jul 30, 2026 | 0001140361-26-030514 | SEC |
| 4 | Jul 24, 2026 | Jul 22, 2026 | 0001140361-26-029636 | SEC |
| 4 | Jul 24, 2026 | Jul 22, 2026 | 0001140361-26-029635 | SEC |
| 4 | Jul 24, 2026 | Jul 22, 2026 | 0001140361-26-029634 | SEC |
| 4 | Jul 24, 2026 | Jul 22, 2026 | 0001140361-26-029633 | SEC |
| 4 | Jul 24, 2026 | Jul 22, 2026 | 0001140361-26-029632 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029341 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029340 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029339 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029338 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029337 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029336 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029335 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029334 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029333 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029332 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029331 | SEC |
| 4 | Jul 22, 2026 | Jul 15, 2026 | 0001140361-26-029330 | SEC |
What changed
Each line is an arithmetic comparison of sourced facts. It is not a thesis.
Research view
Belvedere has not published an initiation or update on ANGIODYNAMICS INC. Universe inclusion is not a rating, a forecast, or coverage in the sell-side sense.
Research Radar
| Kind | Change | Explanation | Source | Date |
|---|---|---|---|---|
| Cash | $53.9M | Cash and cash equivalents were $53.9M as of the latest reported balance-sheet date. | 10-K · CashAndCashEquivalentsAtCarryingValue | Jul 14, 2026 |
| Share count | $41.7M | Shares outstanding were 41,700,419 as of the latest reported date. | 10-K · CommonStockSharesOutstanding | Jul 14, 2026 |
| Revenue | +8.9% | Revenue increased +8.9% ($72.0M to $78.4M; Q1 2025 vs Q1 2026). | 10-Q · RevenueFromContractWithCustomerExcludingAssessedTax | Apr 2, 2026 |
| Revenue acceleration | -0.1 pp | Quarterly revenue YoY growth moved from +9.0% to +8.9% (-0.1 percentage points). | 10-Q · BelvedereRevenueGrowthYoY | Apr 2, 2026 |
| Margin change | $0.529 | Reported gross margin was +52.9% in the latest comparable period. | 10-Q · BelvedereGrossMargin | Apr 2, 2026 |
Rankings
- Strongest Balance Sheets · rank 27 · +20.2%
- Belvedere Undercoverage Screen · rank 4 · 46
- Healthcare Companies by Revenue Growth · rank 5 · +8.9%
Industry context
ANGIODYNAMICS INC is mapped to Healthcare (Surgical & Medical Instruments & Apparatus) from SIC metadata on the SEC submission. Mapping is a classification convenience, not a claim that every peer is economically comparable.
Belvedere Research Profile
This measures researchable information characteristics. It is not investment advice, a credit rating, or a buy/sell/hold recommendation.
Presence of core income-statement, cash-flow and balance-sheet concepts in SEC XBRL.
Comparable-period revenue history and operating-result availability.
Availability of margin, cash-flow and per-share concepts used in screening.
SEC periodic reports, current reports, proxy statement and website identified in submissions.
Distinct filing years in the current archive window plus comparable prior-period revenue.
Risks
Belvedere does not manufacture generic risk language. Material risks are those the issuer discloses in its periodic reports, particularly Item 1A of the latest Form 10-K.
A Form 10-K was not present in the current filing window.
Sources
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q1 2026
- Filed
- Apr 2, 2026
- Accession
- 0001628280-26-023008
- Concept
- RevenueFromContractWithCustomerExcludingAssessedTax
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q1 2026
- Filed
- Apr 2, 2026
- Accession
- 0001628280-26-023008
- Concept
- BelvedereRevenueGrowthYoY
(RevenueFromContractWithCustomerExcludingAssessedTax 2026-02-28 / RevenueFromContractWithCustomerExcludingAssessedTax 2025-02-28) - 1
View filing- Source
- U.S. Securities and Exchange Commission
- Form
- 10-K
- Period
- May 31, 2026
- Filed
- Jul 14, 2026
- Accession
- 0001628280-26-048138
- Concept
- CashAndCashEquivalentsAtCarryingValue
Disclosure
Belvedere Research publishes informational analysis. Nothing on this site is investment advice, an offer, or a solicitation to buy or sell any security.
This page is a company intelligence / data profile. It is not a research report unless a dated note is attached above. Rankings appearing here are independent of any issuer compensation.
Frequently asked questions
- What does ANGIODYNAMICS INC do?
- ANGIODYNAMICS INC (ANGO) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
- What industry is ANGIODYNAMICS INC in?
- ANGIODYNAMICS INC is classified in Healthcare (Surgical & Medical Instruments & Apparatus).
- When did ANGIODYNAMICS INC last file a periodic report?
- ANGIODYNAMICS INC last filed a 4 on Jul 31, 2026 (accession 0001140361-26-030514).
- What was ANGIODYNAMICS INC's latest revenue?
- $78.4M for Q1 2026, sourced from 10-Q filed Apr 2, 2026.
- Does Belvedere cover ANGIODYNAMICS INC?
- ANGIODYNAMICS INC is in the Belvedere universe. Presence in the universe is not the same as active initiation coverage.